ArticleJournal of translational medicine2014
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
Article in Journal of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 91 citations in OpenAlex.
- A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.Neuro-oncology · 2025Trial
- Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.The oncologist · 2024Trial
- Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in PediatricJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Ganglioglioma in children and young adults: single institution experience and review of the literature.Journal of neuro-oncology · 2018Trial
- Ganglioglioma and gangliocytoma: a review for pathologists.Journal of pathology and translational medicine · 2026Article
- Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- VOPP1::EGFR fusion is associated with NFκB pathway activation in a glioneural tumor with histological features of ganglioglioma.Acta neuropathologica communications · 2025Article
- How modern treatments have modified the role of surgery in pediatric low-grade glioma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Chemotherapy in pediatric low-grade gliomas (PLGG).Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Updates on management of gliomas in the molecular age.World journal of clinical oncology · 2024Review
- A rare tumor in the sellar region: ganglioglioma, a case report and a general overview.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Review
- Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy.Frontiers in oncology · 2023Review
- Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report.BMC pediatrics · 2022Article
- Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors.Biomedicines · 2022Review
- Medical Treatment of Pediatric Low-Grade Glioma.Brain tumor research and treatment · 2022Review
- Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primaryFrontiers in oncology · 2022Article
- Intradural Pediatric Spinal Tumors: An Overview from Imaging to Novel Molecular Findings.Diagnostics (Basel, Switzerland) · 2021Review
- Treatment ofSurgical neurology international · 2021Article
- Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.The oncologist · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGanglioglioma (GG) and pilocytic astrocytoma (PA) represent the most frequent low-grade gliomas (LGG) occurring in paediatric age. LGGs not amenable of complete resection (CR) represent a challenging subgroup where traditional treatments often fail. Activation of the MAP Kinase (MAPK) pathway caused by the BRAFV600E mutation or the KIAA1549-BRAF fusion has been reported in pediatric GG and PA, respectively. CASE PRESENTATION: We report on a case of BRAFV600E mutated cervicomedullary GG treated with standard chemotherapy and surgery. After multiple relapse, BRAF status was analyzed by immunohistochemistry and sequencing showing a BRAFV600E mutation. Treatment with Vemurafenib as single agent was started. For the first time, a radiological and clinical response was obtained after 3 months of treatment and sustained after 6 months.
conclusionOur experience underline the importance of understanding the driver molecular alterations of LGG and suggests a role for Vemurafenib in the treatment of pediatric GG not amenable of complete surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.